Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
- DOI
- 10.1002/path.6280
- Published
- 2024 Jun
- Container
- The Journal of pathology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/path.6280,
title = {Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.},
author = {Choo N and Keerthikumar S and Ramm S and Ashikari D and Teng L and Niranjan B and Hedwards S and Porter LH and Goode DL and Simpson KJ and Taylor RA and Risbridger GP and Lawrence MG},
year = {2024},
journal = {The Journal of pathology},
doi = {10.1002/path.6280},
url = {https://doi.org/10.1002/path.6280}
}RIS
TY - JOUR TI - Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer. AU - Choo N AU - Keerthikumar S AU - Ramm S AU - Ashikari D AU - Teng L AU - Niranjan B AU - Hedwards S AU - Porter LH AU - Goode DL AU - Simpson KJ AU - Taylor RA AU - Risbridger GP AU - Lawrence MG PY - 2024 JO - The Journal of pathology DO - 10.1002/path.6280 UR - https://doi.org/10.1002/path.6280 ER -
APA
N, C., S, K., S, R., D, A., L, T., B, N., S, H., LH, P., DL, G., KJ, S., RA, T., GP, R., & MG, L. (2024). Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.. The Journal of pathology. https://doi.org/10.1002/path.6280
Source records
- pubmed · retrieved 2026-09-26T07:09:20.458Z